JMIR Publications announces sponsorship of BioMedEng26 conference in Liverpool
Business Announcement
Updates every hour. Last Updated: 26-Oct-2026 18:17 ET (26-Oct-2026 22:17 GMT/UTC)
Researchers at the Icahn School of Medicine at Mount Sinai have identified immune system changes that can be detected up to 10 years before inflammatory bowel disease (IBD) develops, offering new insight into how the disease begins.
Insilico Medicine (“Insilico”, HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, is addressing this critical unmet need by using AI to uncover novel biological mechanisms and develop innovative therapies. The company recently announced the nomination of ISM9528 as a Preclinical Candidate Compound (PCC) for pain management. Identified by PandaOmics, ISM9528 is a potential first-in-class, brain-penetrant, orally available inhibitor of Target Z that offers a novel, non-opioid treatment approach by acting on a previously unexplored biological mechanism. Notably, this marks the 31st PCC nominated by Insilico since 2021, further validating the company’s AI-driven R&D capabilities.
Directed rotational motion is widespread in nature and technology. At small scales, however, it is difficult to generate. . Researchers from the Karlsruhe Institute of Technology (KIT) and partners in China are now presenting a mechanism in which flows at a water surface alone can cause a floating object to rotate controllably in a single direction. Using this mechanism, they assembled ultrathin fibers into structured bundles – for example to produce low-loss high-frequency transmission lines or surgical suture. The findings were published in Science Advances. (DOI: 10.1126/sciadv.aed5495)
Hepatocytes, the primary functional cells of the liver, release soluble Tim-3 protein during drug-induced injury, and this protein acts as a protective feedback signal to limit excessive immune cell infiltration in the liver. A new study reveals that hepatocyte-derived sTim-3 could bind to Galectin-3 and Galectin-9 to suppress monocyte and macrophage recruitment, thereby reducing tissue necrosis and preserving liver function. The findings identify sTim-3 as a potential therapeutic target for drug-induced liver injury.